Logotipo do repositório
 

Publicação:
Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy

dc.contributor.authorJordão, Marcelo Lopes da Silva
dc.contributor.authorHatanaka, Marcelo
dc.contributor.authorOgundele, Abayomi
dc.contributor.authorSilva, Maria Rosa Bet de Moraes [UNESP]
dc.contributor.authorVessani, Roberto Murad
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionGlobal Medical Affairs
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionServiço Social da Construção Civil do Estado de São Paulo (SECONCI-SP)
dc.date.accessioned2015-12-07T15:30:59Z
dc.date.available2015-12-07T15:30:59Z
dc.date.issued2014
dc.description.abstractTo assess the intraocular pressure (IOP)-lowering effect of travoprost 0.004%/timolol 0.5% fixed-dose combination (TRAV/TIM-FC) in patients not achieving the target IOP of ≤18 mmHg while on timolol 0.5% (TIM) monotherapy. A multicenter, prospective, open-label study (NCT01336569) was conducted in patients with open-angle glaucoma or ocular hypertension. Eligible patients were receiving TIM monotherapy with a screening/baseline IOP of 19-35 mmHg in ≥1 eye. TIM was discontinued on the baseline visit day (no washout period) and TRAV/TIM-FC was initiated and administered once daily at 8 pm for 4-6 weeks. The primary efficacy variable was mean change in IOP from TIM-treated baseline to study end, measured by Goldmann applanation tonometry. Results were analyzed by analysis of variance and paired samples t-test (5% significance). A total of 49 patients were enrolled (mean age, 63 [range, 42-82] years; 55.1% White; 73.5% women), and 45 were included in the intent-to-treat (ITT) population. Mean duration of treatment with TRAV/TIM-FC was 31 days. Mean ± standard deviation IOP reduction from baseline (TIM) to the follow-up visit (TRAV/TIM-FC) was -5.0±3.6 mmHg. IOP decreased significantly (P<0.0001) from baseline (22.1±2.6 mmHg) to study end (17.1±3.9 mmHg) in the ITT population, with a mean IOP reduction of 22.3%. Most patients (n=33/45; 73.3%) achieved IOP ≤18 mmHg. Two patients experienced a total of four adverse events (AEs), including a patient who reported one serious AE (enterorrhagia) that was considered unrelated to treatment, and a patient who reported one event each of drug-related redness, pruritus, and foreign body sensation. Most patients (n=47/49; 95.9%) reported no AEs. TRAV/TIM-FC lowered IOP in patients who were not at target IOP while receiving TIM monotherapy, with most patients achieving an IOP ≤18 mmHg with TRAV/TIM-FC. TRAV/TIM-FC was well tolerated in this population.en
dc.description.affiliationFaculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), São Paulo, SP, Brasil
dc.description.affiliationFaculdade de Medicina (FMUSP), Universidade de São Paulo, São Paulo, SP, Brasil
dc.description.affiliationGlobal Medical Affairs, Alcon Laboratories, Inc., Fort Worth, TX, USA
dc.description.affiliationFaculdade de Medicina de Botucatu (FMB), Universidade Estadual Paulista (UNESP), Botucatu, SP, Brasil
dc.description.affiliationHospital Geral de Itapecerica da Serra, Serviço Social da Construção Civil do Estado de São Paulo (SECONCI-SP), Itapecerica da Serra, SP, Brasil
dc.description.affiliationUnespUniversidade Estadual Paulista, Faculdade de Medicina de Botucatu
dc.format.extent1527-1534
dc.identifierhttp://dx.doi.org/10.2147/OPTH.S66613
dc.identifier.citationClinical Ophthalmology (auckland, N.z.), v. 8, p. 1527-1534, 2014.
dc.identifier.doi10.2147/OPTH.S66613
dc.identifier.filePMC4144930.pdf
dc.identifier.issn1177-5467
dc.identifier.lattes5988776856320701
dc.identifier.pmcPMC4144930
dc.identifier.pubmed25170245
dc.identifier.urihttp://hdl.handle.net/11449/131028
dc.language.isoeng
dc.publisherDove Press Ltd
dc.relation.ispartofClinical Ophthalmology (auckland, N.z.)
dc.relation.ispartofsjr1,035
dc.rights.accessRightsAcesso aberto
dc.sourcePubMed
dc.subjectDuotrav®en
dc.subjectIntraocular pressureen
dc.subjectPrimary open-angle glaucomaen
dc.subjectTime since diagnosisen
dc.titleSafety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapyen
dc.typeArtigo
dcterms.rightsHolderDove Press Ltd
dspace.entity.typePublication
unesp.author.lattes5988776856320701
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Medicina, Botucatupt
unesp.departmentOftalmologia, Otorrinolaringologia e Cirurgia de Cabeça e Pescoço - FMBpt

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
PMC4144930.pdf
Tamanho:
418.53 KB
Formato:
Adobe Portable Document Format